

Cumulative Index 2005

Note: Page numbers of article titles are in **boldface** type.

A

- Accreditation Council for Graduate
Medical Education program, fine
needle aspiration requirements of,
639
- Acinar cells, calcium disturbances in, in
pancreatitis, 2-4
- Acquired immunodeficiency syndrome.
See Human immunodeficiency virus
infection.
- Acromegaly, colorectal cancer in, 147
- Acute lymphoblastic leukemia, stem cell
transplantation for, 528-531
- Acute myeloid leukemia, stem cell
transplantation for, 522-524
- Acute pancreatitis, **17-37**
clinical course of, 17
definition of, 20
genetic factors in, 31-32
mortality in, 17, 20, 23-24
multi-system organ failure in, 19-20
necrosis in, 19, 23-24
pathogenesis of, **1-15**
calcium signaling disturbances in,
2-4
cathepsin B in, 7-9
trypsin in, 9-11
zymogen activation in, 5-9
pathophysiology of, 18-19
severity of
defining, 20
predictors of, 20
clinical assessment in, 23
computed tomography in,
24-25
genetics, 31-32
inflammation markers in,
25-29
laboratory tests in, 23-24
marker combinations in, 31
multi-factorial scoring
systems for, 21-23
observations in, 23
pancreas-specific markers
in, 29-31
phospholipase A-2 in, 31
treatment of, 20
- Acute Physiology and Chronic Health
Evaluation (APACHE) II criteria, in
acute pancreatitis, 20, 22-23
- Adenofibroma, metanephric, 388-390
- Adenoid cystic carcinoma, of breast,
cytomorphology of, 764-766
- Adenoma(s)
breast
lactating, cytomorphology of,
693
tubular, cytomorphology of,
693, 698
renal
classification of, 233, 235-239
metanephric, 292, 379-384
papillary, 284, 286
- Adenomyoepithelioma, of breast,
cytomorphology of, 698-701
- Adenosis tumor, of breast,
cytomorphology of, 698
microglandular, 694
sclerosing, 694
- Adrenal glands, renal cell carcinoma
spread to, 444
- Adrenal rests, 232-233
- Adult respiratory distress syndrome, in
acute pancreatitis, 19
- AE1/AE3, in renal cell carcinoma, 249,
251
- AIDS. *See* Human immunodeficiency
virus infection.
- Air drying, of breast cytology specimens,
640-643
- Albarran and Imbert renal tumor
classification, 234

- Alcoholic pancreatitis
CFTR gene mutations in, 92-93
 pancreatic secretory trypsin inhibitor
 Kazal type in, 67-68
- Algorithms, prognostic, for renal cell carcinoma surgical treatment, 452-456
- ALL (acute lymphoblastic leukemia), stem cell transplantation for, 528-531
- Allocler, for skin coverage, 592
- Alpha-TFEB* gene fusion, in renal carcinoma, 370-375
- Alveolar soft part sarcoma, renal, 363-367, 369-370
- American Association of Blood Banks
 accreditation by, 488, 490, 492-493
 standards of, 488, 490, 492-493
- American Association of Tissue Banks
 accreditation by, 488, 490-493
 Skin Council of, 595-596
 standards of, 488, 490-493, 512-513
- American College of Radiology Breast Imaging Reporting and Data System (BIRADS), 674-676, 733-734
- American Society of Cytology
 cytologic grading recommendations of, 747-749
 fine needle aspiration requirements of, 639-640
 report terminology recommendations of, 753, 756
- AML (acute myeloid leukemia), stem cell transplantation for, 522-524
- Amsterdam criteria, for hereditary nonpolyposis colorectal cancer, 187-189
- Amylase, in pancreatitis, 29
- Anaplasia, in nephroblastoma, 348-350
- Anemia
 aplastic, stem cell transplantation for, 524-526
 in colorectal cancer, 148
- Angiomyolipoma, epithelioid, renal, 331, 405-408
- Anisonucleosis, in breast cancer, 734, 736
- Anterior lamellar keratoplasty, 611-613
- Antibiotics, for cardiovascular tissue disinfection, 576-577
- Antimitochondrial antibody stain, for oncocyoma, 320
- Aortic grafts. *See* Cardiovascular tissue grafts.
- APACHE (Acute Physiology and Chronic Health Evaluation) II criteria, in acute pancreatitis, 20, 22-23
- APC* gene mutations
 in colorectal cancer, 137, 139-140, 142
 in gastric cancer, 209
 pancreatic carcinoma risk in, 121
- Aphidicolin-inducible fragile site, mutations at, in papillary renal cell carcinoma, 285
- Aplastic anemia, stem cell transplantation for, 524-526
- Apocrine carcinoma, of breast, cytomorphology of, 766-767
- Apoptosis, in *Helicobacter pylori* infections, 203-204
- Aspirin, for colorectal cancer prevention, 158-159
- ASPL-TFE3* gene fusion, in renal carcinoma, 364-366, 369-370
- Assisted reproduction technologies, cells and tissues for. *See* Reproductive cell and tissue banking.
- Ataxia-telangiectasia, pancreatic carcinoma risk in, 122
- Atlanta International Symposium on Acute Pancreatitis, acute pancreatitis classification of, 20
- ATM* gene mutations, pancreatic carcinoma risk in, 122
- Atrophy, gastric, in *Helicobacter pylori* infections, 200-201
- Atypical hyperplasia, of breast, cytomorphology of, 718-724, 830-832
- Autodigestion, in pancreatitis, 18-19
 protection against, 63-64
- Autologous tissue donation, retrieval of, 480
- Azathioprine, for skin graft rejection, 594

B

- B lymphocytes, depletion of, for islet cell transplantation, 550-551
- B72.3 monoclonal antibody, in atypical breast hyperplasia, 723

- Barium enema, in colorectal cancer, 151
- Bcl-2 protein, in oncocyoma, 320
- Beckwith-Wiedemann syndrome, nephroblastoma in, 343, 346
- Bell, Elexious Thompson, renal tumor classification of, 235-236
- Beta cell transplantation. *See* Islet cell replacement therapy.
- Bethesda criteria, for hereditary nonpolyposis colorectal cancer, 187-189
- BHD* gene mutations, 270
- Binney renal tumor classification, 233
- Biomechanical properties, of bone and soft tissue grafts, 511-512
- Biopsy
- of breast
 - core needle, 635-637, 658-663, **679-688**
 - fine needle aspiration. *See* Breast lesions, fine needle aspiration biopsy in.
 - of colon polyps, 160
- BIRADS (American College of Radiology Breast Imaging Reporting and Data System), 674-676, 733-734
- Birt-Hogg-Dubé syndrome, renal neoplasms in, 269-270, 328-329
- oncocyosis, 326
- renal cell carcinoma, 269-270
- Black's nuclear grading scheme, for breast carcinomas, 748-749, 811-812
- Bleeding
- in colon polyps, 148
 - in colorectal cancer, 145, 148, 150-151
- Blood, testing of, in tissue donor, 478
- Bloom syndrome, nephroblastoma in, 343, 346
- Bone grafts, **499-518**
- allograft, versus autologous, 499
 - alternatives to, 515
 - autologous
 - incorporation of, 500
 - versus allograft, 499
 - bone morphogenetic proteins and, 501-502
 - cancellous, 500, 505
 - clostridial infection transmission in, 489
 - combination cortical and cancellous, 500
 - complaints about, 514
 - cortical, 500, 505
 - demineralized, 501-502, 505
 - distribution of, 514
 - documentation of, 514
 - freeze drying of, 512-513
 - goals of, 500-501
 - HIV transmission in, 487
 - immunology of, 475, 502-503
 - incoming, inspection of, 513-514
 - incorporation of, 499-501
 - indications for, 483, 504-505
 - mechanical properties of, 511-512
 - osteoarticular, 503, 507
 - osteoconduction in, 500
 - packaging of, 509
 - physical modification of, 501
 - processing of, 504-505, 508-512
 - rehydration of, 513
 - soft tissue grafts combined with, 507
 - specialty, 505-506
 - sterilization of, 510-511
 - storage of, 512-513
 - tissue engineering for, 501
 - types of, 504
- Bone marrow transplantation. *See* Stem cell transplantation.
- Bone morphogenic proteins, in bone grafts, 501-502
- Bone-patellar tendon-bone grafts, 507
- Botryoid nephroblastoma, 367
- BRCA* gene mutations, pancreatic carcinoma risk in, 121-122, 124-126
- Breast cancer
- carcinoma with choriocarcinomatous features, cytomorphology of, 771-772
 - core needle biopsy in
 - costs of, 658
 - versus fine needle aspiration biopsy, 635-637, 658-663, **679-688**
 - cytomorphology of, **733-760, 761-775**
 - accuracy of, 750-752
 - adenoid cystic carcinoma, 764-766
 - apocrine carcinoma, 766-767
 - carcinoma with
 - choriocarcinomatous features, 771-772
 - diagnostic criteria for, 734-735
 - ductal carcinoma and ductal carcinoma in situ, 735-738, 754-755

Breast cancer (*continued*)

- ductal lavage for, 833-839
- ductoscopy for, 792, **845-850**
- false diagnosis in, 751-752, 754-755
- fine needle aspiration biopsy in. *See* Breast lesions, fine needle aspiration biopsy in.
- for grading, 747-749
- lipid-rich carcinoma, 769-771
- lobular carcinoma and lobular carcinoma in situ, 736, 739-740, 754-755
- medullary carcinoma, 736, 746-747
- metaplastic carcinoma, 762-764
- mucinous (colloid) carcinoma, 736, 745, 789
- nipple fluid, **787-794**
- papillary carcinoma, 736, 742-745
- report terminology for, 753-756
- secretory carcinoma, 767-769
- squamous cell carcinoma, 761-762
- tubular carcinoma, 736, 741-742
- within triple test context, 733-734
- familial, pancreatic carcinoma risk in, 121-122
- intraoperative imprint cytology in, **795-807**
- prognostic factors in, **809-825**
 - DNA ploidy, 814-816
 - HER-2/neu* oncogene, 816-818
 - hormone receptors, 812-814
 - lymph node status, 810
 - nuclear grade, 811-812
 - p53 tumor suppressor, 818-819
 - tumor size, 810-811
 - tumor type, 811

Breast lesions

- benign, cytomorphology of, **689-712**
 - epithelial, 696-698
 - fibroepithelial, 700-701
 - in males, 696, 754-755
 - inflammatory, 689-691
 - lymphohistiocytic, 705-706
 - mesenchymal, 701-705
 - myoepithelial, 698-700
 - pregnancy-related changes, 692-693, 754-755
 - proliferative, 694-696
 - treatment-induced changes, 691-692
- common malignant, cytomorphology of, **733-760**
- core needle biopsy in

costs of, 658

versus fine needle aspiration biopsy, 635-637, 658-663, **679-688**

cytomorphology of

- benign, **689-712**
- directed vacuum-assisted biopsy in, 659-667
- ductoscopy in, 792, **845-850**
- fine needle aspiration biopsy in. *See* Breast lesions, fine needle aspiration biopsy in.
- in cancer, **733-760, 761-775**
- in fibrocystic change, **713-731**
- in high-risk proliferative disease, **713-731**
- in premalignant disease, **713-731**
- in proliferative disease, 694-696
- intraoperative imprint cytology in, **795-807**
- nipple fluid for, **787-794**
- diagnostic terminology of, 644-646
- ductal lavage in, 833-839
- ductoscopy in, 792, **845-850**
- fine needle aspiration biopsy in, **631-654**
 - ancillary studies in, 646-649
 - "blind" (in clinically normal tissue), 634, 647-648
 - credentialing for, 638-640
 - diagnostic terminology in, 644-646
- for prognosis, **809-825, 829-833**
- image-directed, **655-678**
 - assessment categories in, 674-676
 - cyst aspiration, 670-672
 - cytologic interpretation in, 674
 - cytology limitations in, 657-659
 - equipment for, 656-657
 - magnetic resonance imaging, 667-668
 - solid masses, 672-674
 - stereotactic, 636-637, 664-667
 - ultrasound, 637, 663-664, 667-670
 - versus core needle biopsy, 658-663
- in benign disease, **689-712**
- in common malignant tumors, **733-760**
- in fibrocystic change, **713-731**
- in high-risk proliferative disease, **713-731**
- in premalignant disease, **713-731**

- in rare malignant tumors, **761-775**
- indications for, 633-637
- medical-legal issues in, **777-785**
- post-biopsy recommendations in, 650-651
- practice guidelines for, 631-633
- prevailing recommendations versus contemporary practices in, **631-654**
- random periareolar, 648
- technique for, 640-644
- training for, 638-640
- versus core needle biopsy, 635-637, 658-663, **679-688**
- intraoperative imprint cytology in, **795-807**
- malignant. *See* Breast cancer.
- nipple fluid cytology in, **787-794**
- nonpalpable, **655-678**
 - core needle biopsy in, 658-663, 682-683
 - fine needle aspiration biopsy in, 656-659, 682
 - recommendations for, versus contemporary practices, **631-654**
- image-guided biopsy of
 - BIRADS criteria for, 674-676
 - cyst aspiration, 670-672
 - cytologic interpretation in, 674
 - magnetic resonance imaging in, 667-668
 - solid mass, 672-674
 - stereotactic, 664-667
 - ultrasound, 663-664, 668-670
- rare malignant, cytomorphology of, **761-775**

C

- Cadherins, in *Helicobacter pylori* infections, 203
- CagA, of *Helicobacter pylori*, gastric cancer and, 200, 203
- Calcific pancreatitis, tropical, 55, 66-67
- Calcium phosphate, as bone graft substitute, 515
- Calcium receptor, defects of, in hereditary pancreatitis, 74
- Calcium signaling, disturbances of, in pancreatitis, 2-4
- Cam 5.2, in renal cell carcinoma, 249
- Cancer
 - breast. *See* Breast cancer.
 - colorectal. *See* Colorectal cancer.
 - gastric. *See* Gastric cancer.
 - ovarian, familial, pancreatic carcinoma risk in, 121-122
 - pancreatic. *See* Pancreas, cancer of.
- Candidiasis, transmission of, in tissue grafts, 488
- Carboxypeptidase, early activation of, in pancreatitis, 5-9
- Carboxypeptidase B activation protein, in pancreatitis, 30
- Carcinoembryonic antigen, in colorectal cancer, 148-149
- Carcinoma
 - adenoid cystic, of breast, 764-766
 - apocrine, of breast, 766-767
 - collecting duct. *See* Collecting duct carcinoma.
 - cystic, of breast, 752
 - ductal, 735-738, 754-755
 - lipid-rich, of breast, 769-771
 - lobular, of breast, 736, 739-740, 754-755
 - medullary, of breast, 736, 746-747
 - metaplastic, of breast, 762-764
 - mucinous, tubular, and spindle cell, 393-398
 - mucinous (colloid), of breast, 736, 745, 789
 - pancreatic. *See* Pancreas, cancer of.
 - papillary, of breast, 736, 742-745
 - renal cell. *See* Renal cell carcinoma(s).
 - sarcomatoid carcinoma, renal, 291-292, 419, 440-441
 - secretory, of breast, 767-769
 - squamous cell, of breast, 761-762
 - tubular, of breast, 736, 741-742
 - with choriocarcinomatous features, of breast, 771-772
- Cardiovascular tissue grafts, **571-585**
 - autologous, 579-580
 - cellular, 580-581
 - disease transmission in, 488, 575
 - donor criteria for, 572-574
 - durability of, 578-579
 - history of, 571
 - immunology of, 579
 - indications for, 483
 - processing of, 576-577
 - procurement of, 572
 - retrieval of, 575-576
 - storage of, 577-578
 - thawing of, 578

- Cardiovascular tissue grafts (*continued*)
transport of, 576
types of, 572
- Cartilage grafts. *See* Soft tissue grafts.
- Cathepsin B, in premature digestive protease activation, in pancreatitis, 7-9
- Causation, in malpractice, 779
- CD10, in renal cell carcinoma, 248-250, 252-253
- CD14, in renal cell carcinoma, 252
- CD15, in renal cell carcinoma, 249-250, 254-255
- CD117, in renal cell carcinoma, 249, 251-254
- CDKN* gene mutations, in familial atypical multiple mole melanoma, 118-120
- CDKN2A* gene mutations, in familial pancreatic cancer, 124
- Celecoxib, for colorectal cancer prevention, 159
- Cellularity, in breast cancer, 734, 736
- Centers for Medicare and Medicaid
Services, provisions to increase organ donation, 608
- Ceramic materials, as bone graft substitutes, 515
- CFTR* gene mutations
idiopathic chronic pancreatitis in
alcoholic pancreatitis and, 92-93
clinical features of, 87-88
gene testing in, 82-87, 90-92
pancreatic secretory trypsin inhibitor Kazal type and, 73-74
pathobiology of, 88-90
prevention of, 96
sclerosing cholangitis and, 93
susceptibility to, 95
trypsin inhibitor gene and, 82-87
pancreatic carcinoma risk in, 122
pancreatic disease in, pathobiology of, 79-81
- Chemotherapy
for breast cancer, cytomorphologic changes in, 692
for neuroblastoma, 352
gonadotoxicity of, 558-560
- Cholangitis, sclerosing, *CFTR* gene mutations in, 93
- Cholecystectomy, colorectal cancer after, 147
- Chromophobe renal cell carcinoma, 321-324
eosinophilic variant, 321-324
differential diagnosis of, 331-334
molecular diagnostic techniques for, 288-289
epidemiology of, 321
granular-appearing cells in, 322
gross pathology of, 321
immunohistochemical markers for, 252-255, 323
in Birt-Hogg-Dubé syndrome, 328-329
microscopic pathology of, 321-323, 436
molecular diagnostic techniques for, 288-289, 323
oncocytomas and, 326-328
polygonal type, 322
prognosis for, 418, 439-440, 451-452
sarcomatoid differentiation or transformation of, 323, 441
versus clear cell renal carcinoma with eosinophilic cells, 334
- Chronic pancreatitis
idiopathic. *See* Idiopathic chronic pancreatitis.
in Kazal type pancreatic secretory trypsin inhibitor mutation, 61-78
- Chymotrypsin, activation of, 62-63
- Chymotrypsinogen, action of, 62-63
- CK7
in metanephric adenoma, 380
in renal cell carcinoma, 249, 253-255
- CK8, in renal cell carcinoma, 253, 311-312
- CK18, in clear cell renal cell carcinoma, 311-312
- CK19, in renal cell carcinoma, 253, 311-312
- CK20, in renal cell carcinoma, 254-255
- Claims, legal, review of, in breast fine needle aspiration biopsy, 782-783
- Clear cell renal cell carcinoma, 305-316
clinical features of, 305-306
compact-alveolar pattern of, 308-309
cytology of, 310-311
differential diagnosis of, 312
eosinophilic variant, 329-334

- epidemiology of, 305
 - familial, 260-265
 - gross pathology of, 306-307
 - immunohistochemical markers for, 248-250, 253
 - in Birt-Hogg-Dubé syndrome, 269-270, 328-329
 - in tuberous sclerosis, 271-272
 - microcystic pattern of, 309-310
 - microscopic pathology of, 307-310, 434
 - molecular diagnostic techniques for, 281-283, 311-312
 - prognosis for, 418, 439-440, 451-452
 - sarcomatoid differentiation of, 441
 - tubular pattern of, 309
- Clear cell sarcoma, renal, versus metanephric stromal tumor, 387
- Clostridial infections, transmission of, in bone grafts, 489
- CLTC-TFE3* gene fusion, in renal carcinoma, 364, 367
- Collagenous spherulosis, of breast, cytomorphology of, 694
- Collecting duct carcinoma
- immunohistochemical markers for, 251
 - low-grade (mucinous, tubular, and spindle cell carcinoma), 393-398
 - microscopic pathology of, 437-438
 - molecular diagnostic techniques for, 289-291
 - oncocytic features of, 330
 - prognosis for, 419
 - versus tubulocystic carcinoma, 399-400
- College of American Pathologists, tissue bank accreditation by, 495-496
- Colloid (mucinous) carcinoma, of breast, 736, 745, 789
- Colon
- cancer of. *See* Colorectal cancer.
 - obstruction of, in cancer, 149
 - perforation of, in cancer, 149
 - polyps of
 - cancer arising from, 136-145, 154, 160
 - clinical presentation of, 149-150
 - colonoscopy in, 152-154, 163-164
 - differential diagnosis of, 153-154
 - DNA mismatch repair expression in, 190-191
 - endoscopic mucosal resection for, 161-162
 - genetics of, 137-143
 - histology of, 136-137
 - hyperplastic, 137, 153-154
 - microsatellite instability testing of, 190-191
 - pathology of, 153-154
 - polypectomy for, 159
 - removal of, 159-162
 - screening for
 - in average risk, 150-154
 - in high risk, 154
 - serrated, 137
 - tubulous, 136
 - tubulovillous, 136
 - villous, 136
 - pseudopolyps of, 154
- Colonoscopy, in colorectal cancer, 152-154, 163-164
- Colorectal cancer, 135-177
- carcinoma in situ, 143
 - clinical presentation of, 145, 148-149
 - computed tomography in, 154-156
 - epidemiology of, 135, 144-145
 - genetic factors in, 137-145
 - hereditary nonpolyposis. *See* Hereditary nonpolyposis colon cancer.
 - histology of, 136-137, 143
 - locations of, 143
 - magnetic resonance imaging in, 156
 - metastasis from, 144
 - computed tomography in, 154-156
 - magnetic resonance imaging in, 156
 - microsatellite instability testing in, 184-185, 189-190
 - new developments in, 163-164
 - pathology of, 143-144, 184-185
 - pathophysiology of, 136-143, 160
 - histologic, 136-137
 - molecular, 137-143
 - prevention of, 158-162
 - risk factors for, 144-145
 - screening for, 150-154
 - in average risk, 150-154
 - in high risk, 154
 - underuse of, 135-136
 - sporadic, microsatellite instability testing in, 184-185, 189-190
 - spread of, testing for, 154-156
 - staging of, 143-144, 154-158
 - stool genetic markers for, 162-163
 - ultrasonography in, 156-158
- Comedocarcinoma, cytomorphology of, 724-726

- Communication, for malpractice prevention, 781-782
- Compact-alveolar pattern, of clear cell renal cell carcinoma, 308-309
- Comparative genetic hybridization, for renal neoplasms, 280
- chromophobe renal cell carcinoma, 288
- oncocytoma, 288
- Complex sclerosing lesion, of breast, cytomorphology of, 695
- Computed tomography
- in colorectal cancer, 154-156
- in pancreatitis, 24-25
- Conduct, malpractice and, 778
- Conjunctival limbal cell transplantation, 617-618
- Connective tissue grafts. *See* Soft tissue grafts.
- Consent, for tissue donation, 476-477
- Core needle biopsy, of breast, 635-637, 658-663, **679-688**
- Corneal grafts. *See also* Keratoplasty. indications for, 483
- C-reactive protein, in pancreatitis, 25-26, 31
- Creatinine, in acute pancreatitis, 24
- Credentialing, for breast fine needle aspiration biopsy, 638-640
- Creutzfeldt-Jakob disease, screening for, in tissue donation, 477
- Crohn's colitis, colorectal cancer in, 147
- Cryopreservation
- of bone grafts, 512-513
- of cardiovascular tissue, 577-578
- of embryos, 560, 564-565
- of skin grafts, 600
- of soft tissue grafts, 512-513
- Cullen sign, in pancreatitis, 23
- Cyclooxygenase-2 inhibitors, for colorectal cancer prevention, 159
- Cyclosporine, for skin graft rejection, 594
- Cyst(s)
- breast, aspiration of, 670-672
- pancreatic, molecular diagnosis of, 108-111
- Cystic carcinoma, of breast, cytomorphology of, 752
- Cystic fibrosis, pancreatic disease in, **79-100**
- alcoholic pancreatitis and, 92-93
- carcinoma, 122
- genetic factors in, 90-92
- in cystic fibrosis carriers, 93-95
- pathobiology of, 79-81
- prevention of, 96
- sclerosing cholangitis and, 93
- susceptibility to, 95
- Cystic nephroma, 354-355
- Cystic partially-differentiated nephroblastoma, 354-355
- Cytokeratin. *See also* CK.
- in renal cell carcinoma, 249, 251, 311-312
- Cytokines. *See also specific cytokines.*
- in acute pancreatitis, 28-29
- in *Helicobacter pylori* infections, 201, 203
- Cytology. *See also* Cytomorphology.
- in clear cell renal cell carcinoma, 310-311
- Cytomegalovirus infections, from skin grafts, 593-594
- Cytomorphology
- of breast lesions
- benign, **689-712**
- common malignant, **733-760**
- core needle biopsy in, 635-637, 658-663, **679-688**
- fine needle aspiration biopsy in.
- See* Breast lesions, fine needle aspiration biopsy in.
- in fibrocystic change, **713-731**
- in high-risk proliferative disease, **713-731**
- in premalignant disease, **713-731**
- medical-legal issues in, **777-785**
- prognostic value of, **809-825, 827-843**
- rare malignant, **761-775**
- of lumpectomy surgical margins, intraoperative, 801-805
- of nipple fluid, **787-794**
- of sentinel lymph nodes, intraoperative, 795-801
- D**
- Daclizumab, for islet cell transplantation, 549-550
- DCC gene, loss of
- in colon cancer, 140, 142
- in gastric cancer, 209

- Death-associated protein-kinase, in gastric cancer, 211-212
- Denys-Drash syndrome, nephroblastoma in, 343-344
- Dermal matrix, acellular, for skin coverage, 592
- Desmoid tumor (fibromatosis), of breast, cytomorphology of, 702-703
- Diabetes mellitus
colorectal cancer in, 147
fibrocalculus pancreatic, 66
in hereditary pancreatitis, 49-52
islet cell replacement for.
 See Islet cell replacement therapy.
- Diet, colorectal cancer and, 146, 158
- Dimethylsulfoxide, for cardiovascular tissue preservation, 577-578
- DIRC2* gene mutations, in familial clear cell renal cell carcinoma, 264
- Discharge, nipple. *See* Nipple fluid cytology.
- DNA
 hypermethylation of, in gastric cancer, 210-212
 methylation of, in colon cancer, 143
- DNA mismatch repair deficiency
 in colon polyps, 190-191
 in gastrointestinal cancer
 clinicopathologic behavior and, 186-187
 colon, 140-142
 for identification, 188-189
 gastric, 205-207
 pathology and, 184-185
 performance of, 183-184
 principles of, 179-181
 test panels for, 181-183
- DNA ploidy, in breast cancer, prognostic value of, 814-816
- Donors, tissue
 bone, 508-509
 cardiovascular, 572-575
 consent forms for, 476-477
 contraindications for donation, 478
 for autologous use, 480
 islet cells, 542-544
 living, tissue retrieval from, 480
 reconstruction of body, 480
 referral of, 476
 screening for risk factors in, 477-478
 skin, 596-597
 soft tissue, 508-509
 testing of, 478-479
 tissue retrieval from, 479-480
- DPC4* gene mutations, in familial pancreatic cancer, 124
- Duct ectasia, cytomorphology of, 690
- Ductal carcinoma and ductal carcinoma in situ, cytomorphology of, 724-727, 735-738, 754-755
- Ductal lavage, for nipple fluid cytology, 791, 833-839
- Ductoscopy, in breast lesions, 792, **845-850**
- Dukes classification, of colorectal cancer, 143-144
- Duty, malpractice and, 779-780
- Dyshesion, in breast cancer, 734, 736
- E**
- E-cadherin
 in *Helicobacter pylori* infections, 203
 in renal cell carcinoma, 249-251, 253-254
- Ecchymosis, in pancreatitis, 23
- Edwards syndrome (trisomy 18),
 nephroblastoma in, 343, 346
- Elastase
 activation of, 62-63
 polymorphonuclear, in acute pancreatitis, 26-27, 31
- Electrocautery, in colon polypectomy, 160
- Electron microscopy, in renal oncocytoma, 319
- Embryos, freezing of, 560, 564-565
- Endoscopic mucosal resection, for colorectal polyps and cancer, 161-162
- Endoscopy, videocapsule, in colorectal cancer, 164-165
- Endotoxemia, in acute pancreatitis, 19
- Environmental factors, in colorectal cancer, - 144, 146
- Eosinophilic variant
 of chromophobe renal cell carcinoma, 288-289, 321-324, 331-334
 of clear cell renal cell carcinoma, 329-334

- Epithelial membrane antigen
 in metanephric adenoma, 380
 in renal cell carcinoma, 249, 252-253, 323
- Epithelioid angiomylipoma, renal, 331, 405-408
- Estrogen receptors, in breast cancer, prognostic value of, 812-814
- Ethical issues
 in reproductive medicine, 565-566
 in tissue donation, 477
- Ethylene oxide sterilization
 of bone grafts, 510-511
 of soft tissue grafts, 510-511
- Ewing renal tumor classification, 234
- EWS-FLI1* gene fusion, in primitive neuroectodermal tumor, 408-410
- Expert review, in breast fine needle aspiration biopsy, 783-784
- Expert witness, in malpractice hearing, 779
- Extracellular signal-regulated MAP kinases, in *Helicobacter pylori* infections, 203
- Eye Bank Association of America, 607-609
 accreditation by, 488, 490-491
 standards of, 488, 490-491
- Eye tissue grafts, **607-624**
 for keratoplasty, 610-616
 corneal layers for, 610-611
 lamellar, 611-614
 penetrating, 614-616
 for limbal stem cell transplantation, 616-620
 conjunctival, 617-618
 ex vivo, 619-620
 keratolimbal, 618-619
 living-related, 618
 indications for, 483
 legislation on, 608-609
 regulations on, 609-610
 scleral, 620-621
- F**
- Familial adenomatous polyposis
 as cancer risk factor, 146
 cancer prevention in, 158-159
 differential diagnosis of, 153
 genetic factors in, 137-139
 pancreatic carcinoma risk in, 122
- Familial atypical multiple mole melanoma, pancreatic carcinoma risk in, 118-120
- Familial breast cancer, pancreatic carcinoma risk in, 121-122
- Familial nephroblastoma, 345
- Familial ovarian cancer, pancreatic carcinoma risk in, 121-122
- Familial pancreatic carcinoma. *See* Hereditary pancreatic carcinoma.
- Familial renal cell carcinomas, **259-277**
 clear cell, 260-265
 in Birt-Hogg-Dubé syndrome, 269-270
 in von Hippel-Lindau disease, 259-263
 leiomyomatosis with, 267-269
 oncocyoma and, 270-271
 papillary, 265-267, 272
 tuberous sclerosis and, 271-272
 with chromosome 3 translocation, 264
- Fascia grafts. *See* Soft tissue grafts.
- Fat necrosis, in breast, cytomorphology of, 691
- Fecal occult blood testing, in colonic lesions, 150-151
- Fertility, tissue banking for. *See* Reproductive cell and tissue banking.
- FH* gene mutations, in hereditary leiomyomatosis with renal cell carcinoma, 267-269
- FHIT* gene mutations, in clear cell renal cell carcinoma, 264, 282
- Fiber, dietary, for colorectal cancer prevention, 158
- Fibroadenoma, of breast
 cytology limitations in, 657-658
 cytomorphology of, 693, 700-701, 754-755
- Fibrocaltolous pancreatic diabetes, 66
- Fibrocystic breast disease, cytomorphology of, 713-714
- Fibromatosis, of breast, cytomorphology of, 702
- Fine needle aspiration biopsy
 in breast lesions. *See* Breast lesions, fine needle aspiration biopsy in.
 in clear cell renal cell carcinoma, 310-311
- FISH. *See* Fluorescent in situ hybridization (FISH).

- Fisher's grading scheme, for breast carcinomas, 748-749, 811-812
- Fite renal tumor classification, 234
- Flank ecchymosis (Gray-Turner sign), in pancreatitis, 23
- FLII-EWS* gene fusion, in primitive neuroectodermal tumor, 408-410
- Fluorescent in situ hybridization (FISH), for renal neoplasms, 280, 282
chromophobe renal cell carcinoma, 288, 323
oncocytoma, 288
papillary renal cell carcinoma, 286
- Food and Drug Administration, tissue banking regulations of, 487-490, 609-610
- Fractional allelic loss, in pancreatic cancer, 106
- Fragile histidine triad gene mutations, in clear cell renal cell carcinoma, 264, 282
- Fuhrman grade, of renal cell carcinoma nuclei, 448-450
- Fumarate hydratase, defects of, in hereditary leiomyomatosis with renal cell carcinoma, 267-269
- G**
- Galactoceles, cytomorphology of, 693
- Garceau renal tumor classification, 233
- Gastric cancer
Helicobacter pylori-associated, 197-222
cellular apoptosis-proliferation balance in, 203-204
epidemiology of, 198-199
genomic instability in, 205-206
inflammation in, 202
intestinal metaplasia or dysplasia in, 206-214
molecular changes in, 202-205
natural history of, 197-198, 200-202
risk factors for, 198, 200-202
subtypes and, 204-205
surveillance for, 214
transduction pathway imbalance in, 202-203
virulence factors and, 200
microsatellite instability in, 186
- Gene therapy, for islet cell transplantation, 550
- Genetic factors
in familial adenomatous polyposis, 137-139
in hereditary nonpolyposis colon cancer, 137-139
in pancreatic cancer. *See also* Hereditary pancreatic carcinoma.
molecular analysis of, 101-116
in pancreatitis
acute, 31-32
hereditary, 39-46, 54-55
idiopathic chronic, 79-100
pancreatic carcinoma risk and, 120-121
- Giemsa stain, of breast cytology specimens, 641
- Glasgow criteria, modified, for acute pancreatitis, 22-23
- Graft(s). *See specific type, e.g., Bone grafts.*
- Graft-versus-host disease, in stem cell transplantation, 519-520
for acute lymphoblastic anemia, 528-530
for aplastic anemia, 526
- Graft-versus-leukemia effect, 520
- Granular cell tumors, of breast, cytomorphology of, 703-704
- Granulomatous mastitis, cytomorphology of, 690-691
- Grawitz, Paul Albert, renal tumor classification of, 232-233, 235
- Gray-Turner sign, in pancreatitis, 23
- Gynecomastia, cytomorphology of, 696, 754-755
- H**
- Hale's colloidal iron stain
in chromophobe renal cell carcinoma, 323
in renal oncocytoma, 319-320
- Hamartoma, breast, cytology limitations in, 658
- Heidelberg-Rochester Classifications of 1997, for renal tumors, 235-236, 238-242
- Helicobacter pylori*, in gastric carcinogenesis. *See* Gastric cancer, *Helicobacter pylori*-associated.
- Hematocrit, in pancreatitis, 23

- Hematopoietic stem cell transplantation.
See Stem cell transplantation.
- Hepatitis C, transmission of, in tissue grafts, 489
- Hepatocarcinoma-intestine-pancreas/
pancreatitis-associated protein 1, in
pancreatic cancer, 107
- Hepatocyte growth factor/scatter factor, in
hereditary papillary renal cell
carcinoma, 265-267
- Hereditary leiomyomatosis, renal cell
carcinoma with, 267-269
- Hereditary nonpolyposis colon cancer
as cancer risk factor, 147
cancers associated with, 180
criteria for, 187-188
epidemiology of, 180
genetic factors in, 137-139
microsatellite instability testing in,
180-181
for patient identification,
187-189
methods for, 181-184
pathology and, 184-185
MSH6 gene mutations in, 189-190
pancreatic carcinoma risk in, 121
- Hereditary pancreatic carcinoma,
117-133
classification of, 118
familial, 122-126
future perspectives on, 126-128
syndromes associated with, 118-122
- Hereditary pancreatitis, 39-59
complications of, 49-54
pancreatic carcinoma risk in, 52-54,
120-121
pancreatic secretory trypsin inhibitor
expression and. See Pancreatic
secretory trypsin inhibitor.
presentation of, 46-48
protease serine 1 defects in, 39-46,
54-55
symptoms of, 48-50
- Hereditary papillary renal cell carcinoma,
265-267, 285
- HER-2/neu* oncogene, in breast cancer,
648-649, 816-818
- HIV infection. See Human
immunodeficiency virus infection.
- HMB45
in epithelioid angiosarcoma,
406-407
in translocation carcinoma, 370, 373
- Hodgkin's disease, stem cell transplantation
for, 531-532
- Hormone replacement therapy, breast fine
needle aspiration in, 649
- Horseshoe kidney, nephroblastoma in,
341-342
- Human immunodeficiency virus infection
screening for, in tissue donation, 477
transmission of
in eye tissue grafts, 609
in skin grafts, 593-594
in tissue transplantation, 487
- Human leukocyte antigens
in bone grafts, 502-503
in cardiovascular tissue grafts, 579
matching of, in tissue banking, 475
- Hypercalcemia, pancreatitis in, 4
- Hyperglycemia, in acute pancreatitis, 24
- Hypermethylation, in gastric cancer,
210-212
- Hypoxia-inducible factor, regulation of, in
von Hippel-Lindau disease, 262-263
-
- I**
- Idiopathic chronic pancreatitis, 79-100
alcoholic pancreatitis and, 92-93
clinical findings in, 68-70, 87-88
cystic fibrosis and, 95-96
genetic factors in, 82-87
CFTR gene in, 82-87
testing for, 90-92
trypsin inhibitor gene in, 82-87
in cystic fibrosis carriers, 93-95
pancreatic secretory trypsin inhibitor
Kazal type in, 64-65, 67-68
pathobiology of, 79-81, 88-90
prevention of, 96
sclerosing cholangitis and, 93
- Immunodeficiency, primary, stem cell
transplantation for, 533-534
- Immunohistochemical markers, for renal
neoplasms
chromophobe renal cell carcinoma,
252-253, 323
clear cell renal cell carcinoma,
248-250, 311-312
collecting duct carcinoma, 251
epithelioid angiosarcoma, 406-407
metanephric stromal tumor, 386
mixed epithelial and stromal tumor,
404
mucinous, tubular, and spindle
carcinoma, 400-401

- nephroblastoma, 351-352
 oncocyoma, 253-255, 320
 papillary renal cell carcinoma, 250-251
 primitive neuroectodermal tumor, 410
 renal cell carcinomas, **247-257**
 synovial sarcoma, 412
 translocation carcinoma, 367, 369, 375
 tubulocystic carcinoma, 400-401
- Immunoisolation, in islet cell transplantation, 551
- Immunology, of tissue banking, 475
 bone grafts, 502-503
 cardiovascular, 579
- Immunosuppressive therapy, for islet cell transplantation, 549-550
- In vitro fertilization, cells and tissues for.
See Reproductive cell and tissue banking.
- Infections
 in acute pancreatitis, 20
 of skin grafts, 593-594
- Infertility treatment, tissue banking for.
See Reproductive cell and tissue banking.
- Inflammation
 in *Helicobacter pylori* infections, 202
 in pancreatitis, 18-19
- Inflammatory bowel disease, colorectal cancer in, 147
- Inflammatory markers, in acute pancreatitis, **17-37**
- Interleukin(s)
 in acute pancreatitis, 28
 in *Helicobacter pylori* infections, 201, 203
- Intestinal metaplasia, in gastric cancer, 206-214
- Intralobar nephrogenic rests, 353-354, 387
- Intraoperative imprint cytology, in breast cancer
 in lumpectomy margin assessment, 801-805
 in sentinel lymph node assessment, 795-801
- Islet cell replacement therapy, **541-556**
 cell collection for, 542-544
 cell culture for, 546
 cell processing for, 544-546
 contraindications for, 547
 future directions in, 550-553
 history of, 541-542
 immunoisolation for, 551
 immunosuppression before, 549-550
 indications for, 546-547
 infusion in, 548-549
 stem cells for, 552
 tolerance induction in, 550-551
 versus pancreas transplantation, 541
 xenogenic cells for, 551-552
-
- ## J
- Janus kinase 3 deficiency, stem cell transplantation for, 534
- Joint Commission on Accreditation of Health Care Organizations, tissue bank inspections by, 493-494
- Joint grafts. *See* Soft tissue grafts.
- c-JUN N-terminal MAP kinases, in *Helicobacter pylori* infections, 203
- Juvenile polyposis, as cancer risk factor, 147
-
- ## K
- Kazal type pancreatic secretory trypsin inhibitor. *See* Pancreatic secretory trypsin inhibitor, Kazal type.
- Keratinocytes, cultured, application of, skin graft template for, 592
- Keratolimbic allografts, 618-619
- Keratoplasty, 610-616
 corneal layers for, 610-611
 lamellar, 611-614
 penetrating, 614-616
- Kidney
 horseshoe, nephroblastoma in, 341-342
 neoplasms of. *See* Renal neoplasms.
- Ki-67/MIB-1, evaluation for, in breast lesions, 649
- K-ras* gene mutations
 in colon cancer, 141-142
 in gastric cancer, 209
 in pancreatic cancer, 103-104
 in pancreatic cyst, 109
-
- ## L
- Lactating adenoma, cytomorphology of, 693
- Lamellar keratoplasty, 611-614

- Lavage, ductal, for nipple fluid cytology, 791, 833-839
- Legal harm, in breast fine needle aspiration biopsy, 783-784
- Legal issues
 in breast fine needle aspiration biopsy, 777-785
 claims review, 782-783
 communication, 781-782
 duty, 779-780
 expert review, 783-784
 legal harm, 783-784
 misdiagnosis, 783-784
 principles of, 778-779
 in eye tissue grafts, 608-609
 in reproductive medicine, 565-566
- Leiomyomatosis, hereditary, renal cell carcinoma with, 267-269
- Leukemia, stem cell transplantation for
 acute lymphoblastic, 528-531
 acute myeloid, 522-524
- Leukotrienes, in *Helicobacter pylori* infections, 201
- Li-Fraumeni syndrome, nephroblastoma in, 343
- Ligament grafts. *See* Soft tissue grafts.
- Limbal cell transplantation, 616-620
 conjunctival, 617-618
 ex vivo, 619-620
 keratolimbal, 618-619
 living-related, 618
- Linkage analysis, in familial pancreatic carcinoma, 123
- Lipase, in pancreatitis, 29
- Lipid-rich carcinoma, of breast, cytomorphology of, 769-771
- Lipoma, of breast, cytomorphology of, 704
- LKB1* gene mutations, pancreatic carcinoma risk in, 120
- Lobular carcinoma and lobular carcinoma in situ, cytomorphology of, 727-728, 736, 739-740, 754-755
- Loss of heterozygosity
 in colon cancer, 141, 143
 in gastric cancer, 209
 in renal neoplasms, 279-280
 chromophobe renal cell carcinoma, 288-289
 clear cell renal cell carcinoma, 281-283
 collecting duct carcinoma, 289-290
 oncocytoma, 288-289
 papillary renal cell carcinoma, 287-288
- Lumpectomy margins, intraoperative imprint cytology in, 801-805
- Lymph nodes
 axillary, in breast cancer, prognosis and, 810
 renal cell carcinoma extension into, 445-446
 sentinel, in breast cancer, intraoperative imprint cytology in, 795-801
- Lymphohistiocytic proliferations, of breast, cytomorphology of, 705-706
- Lymphoma, stem cell transplantation for, 531-532
- Lynch syndrome. *See* Hereditary nonpolyposis colon cancer.
- Lyophilization, of skin grafts, 600
-
- M**
- MADH4* gene mutations, in familial pancreatic cancer, 124
- Magnetic resonance imaging
 in breast needle biopsy, 667-668
 in colorectal cancer, 156
- Mainz Classification of 1986, for renal tumors, 235, 237-239
- Malabsorption, in hereditary pancreatitis, 51
- Malignant melanoma, in familial atypical multiple mole melanoma, pancreatic carcinoma risk in, 118-120
- Masood Cytology Index, for breast lesions, 728, 839-840
- Mass spectrometry, surface-enhanced laser desorption ionization, in pancreatic cancer, 107
- Mastitis, cytomorphology of, 689-691
- Mayo Clinic, renal cell carcinoma prognostic algorithm and reporting form of, 455-456, 459-460
- Medical-legal issues. *See* Legal issues.
- Medullary carcinoma
 breast, cytomorphology of, 736, 746-747
 renal, 331, 419

- Melan A, in translocation carcinoma, 370
- Melanoma, in familial atypical multiple mole melanoma, pancreatic carcinoma risk in, 118-120
- Melicow renal tumor classification, 233-234
- Memorial Sloan-Kettering Cancer Center, renal cell carcinoma prognostic algorithm of, 452-453
- Meniscus grafts, 508
- Mesenchymal tumors, of breast, cytomorphology of, 701-705
- Mesothelioma, renal cell carcinoma with, 248
- Mesotrypsin, 71
- c-MET* gene mutations, in hereditary papillary renal cell carcinoma, 265-267, 285
- Metal appliances, as bone graft substitutes, 515
- Metanephric neoplasms, **379-392**
adenofibroma, 388-390
adenoma, 292, 379-384
stromal, 384-387
- Metaplastic carcinoma, of breast, cytomorphology of, 762-764
- Metastasis
from colorectal cancer, 144
 computed tomography in, 154-156
 magnetic resonance imaging in, 156
from metanephric adenoma, 383
from nephroblastoma, 351-352
from renal cell carcinoma, 441-442, 445-447, 458
from translocation renal carcinomas, 365
- α -Methylacyl-CoA racemase, in renal cell carcinoma, 249, 251, 253
- Methylation, DNA, in colon cancer, 143
- MHL1* gene mutations, in gastric cancer, 205, 208, 211-212
- MHL3* gene mutations, in gastric cancer, 207
- MHS2* gene mutations, in gastric cancer, 205, 207
- MHS3* gene mutations, in gastric cancer, 205, 207
- Microarray analysis
in breast lesions, 649
in gastric cancer, 213-214
- Microcystic pattern, of clear cell renal cell carcinoma, 309-310
- Microdissection-based genotyping, in pancreatic cancer, 106
- Microglandular adenosis, of breast, cytomorphology of, 694
- Micrografts, skin, 592-593
- Microphthalmia transcription factor, in translocation renal carcinoma, 370, 374-375
- Microsatellite instability testing
in colon polyps, 190-191
in gastrointestinal cancer, **179-196**
 clinicopathological behavior and, 186-187
 for identification, 188-189
 gastric, 186-187, 205-209
 hereditary nonpolyposis colorectal cancer, 180-181, 183-185, 187-191
 high-level, 181-189, 207-209
 low-level, 181-182, 184, 186, 188-189, 207-208
 MSH6 gene mutations in, 189-190
 panels for, 181-183
 pathology and, 184-185
 performance of, 183-184
 principles of, 179-181
 sporadic colorectal cancer, 184-185, 189-190
 versus colon polyps, 190-191
in renal neoplasms, 280
 chromophobe renal cell carcinoma, 288
 clear cell renal cell carcinoma, 281
 oncocytoma, 288
- MiR/TFE family translocation carcinomas, renal, 363-370
- Mismatch repair deficiency. *See* DNA mismatch repair deficiency.
- Mixed epithelial and stromal tumor, renal, 402-405
- MLH* gene mutations
in colon cancer, 138
pancreatic carcinoma risk in, 121
- MLH1* gene mutations
in colon polyps, 190-191

- MLH1 gene** (*continued*)
 in hereditary nonpolyposis colon cancer, 180, 183-185, 188-190
- Molecular techniques**, for renal neoplasms, **279-303**
 chromophobe renal cell carcinoma, 288-289
 clear cell renal cell carcinoma, 281-283
 collecting duct carcinoma, 289-291
 metanephric adenoma, 292
 oncocytoma, 288-289, 320
 papillary adenoma, 284, 286
 papillary renal cell carcinoma, 283-288
 renal cell carcinoma with Xp11.2 translocations, 292-294
 sarcomatoid carcinoma, 291-292
- Monocyte chemotactic protein 1**, in acute pancreatitis, 18, 31-32
- Monomorphism**, in breast cancer, 734, 736
- Monosomy**, of various chromosomes, in collecting duct carcinoma, 289-290
- Mortality**, in stem cell transplantation, 519, 521
- MSH gene mutations**
 in colon cancer, 138
 pancreatic carcinoma risk in, 121
- MSH2 gene mutations**
 in colon polyps, 190-191
 in hereditary nonpolyposis colon cancer, 180-181, 183-184, 188-190
- MSH6 gene mutations**
 in gastric cancer, 205, 207, 209
 in hereditary nonpolyposis colon cancer, 180-181, 184, 189-190
- MUC1 protein**, in renal cell carcinoma, 249-251
- Mucinous, tubular, and spindle cell carcinoma**, 393-398
- Mucinous (colloid) carcinoma**, of breast, 736, 745, 789
- Mucocoele-like lesion**, of breast, cytomorphology of, 697
- Multirray assay**, for colorectal cancer, 163
- Multi-system organ failure**, in pancreatitis, 19-20
- Muscle specific actin**, in atypical breast hyperplasia, 723-724
- MutL protein**
 in gastric cancer, 205, 207
 in hereditary nonpolyposis colon cancer, 180
- MutS protein**
 in gastric cancer, 205
 in hereditary nonpolyposis colon cancer, 180
- Myocardial cells**, transplantation of, 580-581
- Myoepithelial neoplasms**, of breast, cytomorphology of, 698-701
- Myofibroblastoma**, of breast, cytomorphology of, 701
- Myospherulosis**, in breast, cytomorphology of, 691
-
- N**
- National Cancer Institute**, microsatellite instability testing recommendations of, 181
- National Organ and Tissue Donor Act**, on monetary compensation, 477
- Necrosis**
 fat, in breast, cytomorphology of, 691
 in acute pancreatitis, 19, 23-24
 in renal cell carcinoma, prognostic value of, 450-452
- Negligence**, law of, 778
- Neoplasms, renal**. *See* Renal neoplasms.
- Nephrectomy**, specimen handling and reporting after
 partial, 426-427
 radical, 422-425
- Nephroblastic neoplasms**, **341-361**. *See also* Nephroblastoma.
 classification of, 342
 cystic partially-differentiated nephroblastoma, 354-355
 nephroblastomatosis, 352-354
 nephrogenic rests, 352-354
- Nephroblastoma**
 anaplastic, 348-350
 botryoid, 367
 clinical course of, 352
 clinical features of, 345-346
 cystic partially-differentiated, 354-355
 development from nephrogenic rests, 354

- distribution of, 341-342
 - epidemiology of, 341
 - familial disposition to, 345
 - gross pathology of, 346-347
 - immunohistochemical markers for, 351-352
 - metastatic, 351-352
 - microscopic pathology of, 347-350
 - multicentric, 345
 - nephrogenic rests and, 345
 - nuclear unrest in, 350
 - outcome of, 352
 - pathogenesis of, 342-345
 - pathology of, 346-352
 - posttherapy changes in, 351
 - prognosis for, 348-350
 - staging of, 346-347
 - syndromes associated with, 342-345
 - treatment of, 352
 - versus metanephric adenoma, 382-383
 - Nephroblastomatosis, 352-354
 - Nephrogenic rests, 352-354
 - multicentric nephroblastoma and, 345
 - versus metanephric stromal tumor, 387
 - Nephroma, congenital mesoblastic, versus mixed epithelial and stromal tumor, 405
 - Neuroblastoma
 - oncocytoid renal cell carcinoma with, 331
 - stem cell transplantation for, 526-538
 - Neurofibromatosis, type 1, nephroblastoma in, 343
 - Neurolemmoma, of breast, cytomorphology of, 701
 - Nipple fluid cytology, **787-794**
 - in cancer risk assessment, 829-833
 - in Paget's disease, 792
 - in papilloma, 788-790
 - of aspirated fluid, 790
 - of ductal lavage fluid, 791, 833-839
 - of ductoscopic sample, 792, **845-850**
 - of scraped tissue, 792
 - of secretions, 790
 - value of, 787-788
 - Nitric oxide synthase, in *Helicobacter pylori* infections, 205
 - Noncomedo ductal carcinoma in situ, cytomorphology of, 726-727
 - Non-O-TFE3* gene fusion, in renal carcinoma, 364, 367, 369
 - Nonsteroidal anti-inflammatory drugs, for colorectal cancer prevention, 158-159
 - North American National Wilms Tumor Study Group staging system, 346
 - Nuclear factor- κ B, in *Helicobacter pylori* infections, 203
 - Nuclear grade, of renal cell carcinoma, 419, 447-450
 - Nuclear membranes, irregular, in breast cancer, 734, 736
 - Nuclear unrest, in nephroblastoma, 350
 - Nucleoli, prominent, in breast cancer, 734, 736
-
- O**
- Oncoblasts, microscopic appearance of, 319
 - Oncocytes, microscopic appearance of, 318-319
 - Oncocytic renal neoplasms, **317-339**. *See also* Chromophobe renal cell carcinoma; Oncocytomas, renal, differential diagnosis of, 329-334
 - hybrid, 326-327
 - in Birt-Hogg-Dubé syndrome, 328-329
 - oncocytosis, 324-326
 - Oncocytomas, renal, 318-321
 - atypical features in, 319
 - chromophobe renal cell carcinoma and, 326-328
 - differential diagnosis of, 331-334
 - epidemiology of, 318
 - familial, 270-271
 - gross pathology of, 318
 - histology of, 318-320
 - immunohistochemical markers for, 253-255, 320
 - in Birt-Hogg-Dubé syndrome, 328-329
 - metachronous, 326
 - molecular diagnostic techniques for, 288-289, 320
 - multi-focal, 324-326
 - prognosis for, 320-321
 - tubulocystic pattern of, 318
 - Oncocytosis, renal, 324-326
 - Oocytes, banking of, 560
 - cryobiology of, 561-562
 - indications for, 563-564
 - Organ failure, in pancreatitis, 19-20

Osteoarticular grafts, 503, 507
immunology of, 503
storage of, 512-513

Ovary

cancer of, familial, pancreatic carcinoma risk in, 121-122
cancer treatment toxicity to, 558-559
tissue from
autotransplantation of, 563-564
banking of, 560-561, 563-564
cryobiology of, 561-562

P

p16 gene mutations

in familial pancreatic cancer, 124
in pancreatic cyst, 109

p53 gene mutations

in breast cancer, 818-819
in colon cancer, 141-143
in familial pancreatic cancer, 124
in gastric cancer, 209
in pancreatic cyst, 109

Paget's disease, of breast, cytomorphology of, 792

Pancreas

cancer of
epidemiology of, 101
hereditary. *See* Hereditary pancreatic carcinoma.
in hereditary pancreatitis, 52-54, 120-121
molecular diagnosis of, **101-116**
cystic lesions, 108-111
K-ras oncogene in, 103-104
proteomics in, 107-108
specimens for, 102
telomerase activity in, 104-105
tumor suppressor allelic loss analysis in, 105-107
progression of, 102
cysts of, molecular diagnosis of, 108-111
function of, 1
inflammation of. *See* Acute pancreatitis; Chronic pancreatitis; Pancreatitis.
intraepithelial neoplasia of, 102
necrosis of, in acute pancreatitis, 19, 23-24
pseudocyst of, molecular analysis of, 110
transplantation of, versus islet cell transplantation, 541

Pancreatic duct, obstruction of
in acute pancreatitis, 4
in cystic fibrosis, 79-81

Pancreatic secretory trypsin inhibitor (PSTI, SPINK 1)

action of, 18, 62-64
defects of, in hereditary pancreatitis, 54-55
discovery of, 61-62
Kazal type, **61-78**
action of, 63-64
defects of
clinical features of, 68-70
gene-gene interactions in, 73-74
genetic testing in, 74
in alcoholic pancreatitis, 67-68
in chronic pancreatitis, 71-73
in idiopathic chronic pancreatitis, 64-65, 82-87
in tropical pancreatitis, 64-67
pathophysiology of, 70-71
severe, 72-73
protective function of, 63-64
structure of, 54, 63

Pancreatic-associated protein, in pancreatitis, 29

Pancreatitis

acute. *See* Acute pancreatitis.
chronic. *See* Chronic pancreatitis.
hereditary. *See* Hereditary pancreatitis.
idiopathic chronic. *See* Idiopathic chronic pancreatitis.
tropical calcific, 55, 66-67

Pancytokeratin, in renal cell carcinoma, 253

Pap stain, of breast cytology specimens, 640-643

Papillary carcinoma, of breast, cytomorphology of, 736, 742-745

Papillary renal cell adenoma, 284, 286

Papillary renal cell carcinoma
familial, 265-267, 272
hereditary, 265-267, 285
immunohistochemical markers for, 250-251, 381-383
in Birt-Hogg-Dubé syndrome, 328-329
microscopic pathology of, 434-435

- molecular diagnostic techniques for, 283-288
oncocytic features of, 330
papillary thyroid carcinoma with, 272
prognosis for, 418-419, 439-440, 451
sarcomatoid differentiation of, 441
versus clear cell renal cell carcinoma, 312
versus metanephric adenoma, 380-382
- Papillary thyroid carcinoma, papillary renal cell carcinoma with, 272
- Papilloma, breast, cytomorphology of, 696-697, 754-755, 788-790
- Parvalbumin
in oncocytoma, 320
in renal cell carcinoma, 252-253, 323
- Pediatric patients
renal tumors in. *See also* Nephroblastoma.
classification of, 342
stem cell transplantation in, 519-540
autologous, 519
cell harvesting for, 519
for acute lymphoblastic leukemia, 528-531
for acute myeloid leukemia, 522-524
for aplastic anemia, 524-526
for Hodgkin's disease, 531-532
for lymphoma, 531-532
for neuroblastoma, 526-528
for primary immune deficiencies, 533-534
selection of cells for, 520-522
versus adult transplantation, 520
- Penetrating keratoplasty, 614-616
- Perilobar nephrogenic rests, 353
- Peritoneal lavage, in pancreatitis, 23
- Periumbilical ecchymosis, in pancreatitis, 23
- Perlman syndrome, nephroblastoma in, 343, 346
- Peutz-Jeghers syndrome
as cancer risk factor, 147
colon polyps in, 153-154
pancreatic carcinoma risk in, 120
- Phospholipase A-2, in pancreatitis, 31
- Phylloides tumors, breast, cytology limitations in, 657-658
- Physicians Insurers Association of America, 777
- PMS* gene mutations, in colon cancer, 138
- PMS1* gene mutations
in gastric cancer, 205, 207
in hereditary nonpolyposis colon cancer, 181
- PMS2* gene mutations
in gastric cancer, 205, 207
in hereditary nonpolyposis colon cancer, 180
- Polymerase chain reaction
in colorectal cancer, 163
in pancreatic cancer, 106
in translocation-associated gene fusions, 373
- Polymorphonuclear elastase, in pancreatitis, 26-27, 31
- Polyps, colon. *See* Colon, polyps of.
- Posterior lamellar keratoplasty, 613-614
- Postpolypectomy syndrome, 160
- PRCC-TFE3* gene fusion, in renal carcinoma, 364-365, 368-370
- Pregnancy, breast cytomorphology in, 692-693, 754-755
- Primitive neuroectodermal tumor, renal, 408-410
- Procalcitonin, in pancreatitis, 27-28
- Procarboxypeptidase-B, in pancreatitis, 29-30
- Proelastase, action of, 62-63
- Progesterone receptors, in breast cancer, prognostic value of, 812-814
- Proliferative breast disease, cytomorphology of
atypical hyperplasia, 718-724, 830-832
ductal carcinoma in situ, 724-727, 735-738, 754-755
lobular carcinoma in situ, 727-728, 736, 739-740, 754-755
malignant, 717-718
versus nonproliferative breast disease, 714
with atypia, 717
without atypia, 714-717
- Prosthetic heart valves. *See* Cardiovascular tissue grafts.

Protease serine 1 (cationic trypsinogen), defects of
in hereditary pancreatitis, 39-46,
54-55
pancreatic carcinoma risk in,
120-121

Proteomics, in pancreatic cancer, 107-108

PRSS1 gene mutations, in hereditary pancreatitis, 39-46, 73

Pseudoangiomatic stromal hyperplasia, of breast, cytomorphology of, 704-705

Pseudocyst, pancreatic, molecular analysis of, 110

Pseudopolyps, colon, 154

PSF-TFE3 gene fusion, in renal carcinoma, 364, 367

PST1. *See* Pancreatic secretory trypsin inhibitor.

Pulmonary artery grafts. *See* Cardiovascular tissue grafts.

Q

Quality control, in reproductive tissue cryobanking, 566-567

R

Rabies, transmission of, in tissue grafts, 489

Radial scars, of breast, cytomorphology of, 695

Radiation
for bone graft sterilization, 510-511
for soft tissue graft sterilization, 510-511

Radiation therapy
for breast cancer, cytomorphologic changes in, 692
gonadotoxicity of, 558-560

Radiography, in acute pancreatitis, 24

Radiologic Diagnostic Oncology Group Study, of breast fine needle aspiration biopsy, 658-659

Ranson score, for pancreatitis, 20-23

Ras association domain family 1A gene mutations, in clear cell renal cell carcinoma, 282

ras oncogene, in pancreatic cancer, 103-104

RASSF1A gene mutations, in clear cell renal cell carcinoma, 282

Rayer, Pierre François Olive, renal tumor classification of, 231-232

RB gene mutations, in collecting duct carcinoma, 289

Reactive oxygen species, in *Helicobacter pylori* infections, 202, 205

Regulations, tissue banking, 487-498, 609-610

Rejection, of skin grafts, 594

Renal cell carcinoma(s)
adrenal involvement in, 444
chromophobe. *See* Chromophobe renal cell carcinoma.
classification of, 235, 237-239, 418-419, 434-447, 458
clear cell. *See* Clear cell renal cell carcinoma.
completeness of resection of, 420
epidemiology of, 305
familial. *See* Familial renal cell carcinomas.
histologic types of, 418-419, 434-440
immunohistochemical markers for, 247-257
mesothelioma with, 248
metastasis from, 441-442, 445-447, 458
microscopic vascular invasion of, 420-421
nuclear grade of, 419, 447-450
oncocytoid, neuroblastoma with, 331
outcome prediction models for, 421-422
papillary. *See* Papillary renal cell carcinoma.
perinephric fat involvement in, 444-445
primary tumor characteristics in, 442, 444-445, 447
prognosis for, 417-422
after surgical treatment, 433-464
risk factors for, 305
specimen handling and reporting for, 417-432
frozen section, 428-429
in partial nephrectomy, 426-427
in radical nephrectomy, 422-425
morcellated, 427-428
needle core biopsy, 428
prognostic factors in, 417-422
staging of, 420

- surgical treatment of
 prognosis after, **433-464**
 algorithms for, 452-456
 histologic subtype and, 434-440
 necrosis and, 450-452
 nuclear grade and, 447-450
 primary tumor size and, 447
 reporting form for, 459-460
 sarcomatoid differentiation and, 440-441
 TNM classification and, 441-447, 458
 specimen handling and reporting for, 422-427
 tumor size and, 419-420
 with sarcomatoid elements, 291-292
 with Xp11.2 translocation, 292-294, 363-370
- Renal cell carcinoma marker, 247-250, 252-253, 370
- Renal neoplasms. *See also specific types.*
 classification of
 history of, **231-246**
 nephroblastic, 342
 papillary renal cell adenoma, 284
 pediatric, 342
 renal cell carcinoma, 235, 237-239, 418-419, 434-447, 458
 clear cell renal cell carcinoma. *See* Clear cell renal cell carcinoma.
 epithelial, **279-303**
 epithelioid angiomyolipoma, 331, 405-408
 immunohistochemical markers for.
 See specific tumors.
 immunohistochemical markers for.
 metanephric, **379-392**
 mixed epithelial and stromal, 402-405
 molecular diagnosis of, **279-303**
 mucinous, tubular, and spindle cell carcinoma, 393-398
 nephroblastic, **341-361**
 oncocytic, **317-339**. *See also* Oncocytomas, renal.
 primitive neuroectodermal, 408-410
 rare, **393-416**
 renal cell carcinoma. *See* Renal cell carcinoma(s); *specific types.*
 specimen handling and reporting for, **417-432**
 synovial sarcoma, 411-413
 translocation carcinomas, **363-378**
 tubulocystic carcinoma, 393-395, 398-402
- Renal vein, renal cell carcinoma extension into, 445
- Reproductive cell and tissue banking, **557-569**
 chemotherapy toxicity and, 558-560
 cryobiology of, 561-562
 ethical issues in, 565-566
 indications for, 483, 562-565
 legal issues in, 565-566
 options for, 560-561
 quality control in, 566-567
 radiation therapy toxicity and, 558-560
- Restriction fragment length polymorphism analysis, in renal neoplasms
 chromophobe renal cell carcinoma, 288
 clear cell renal cell carcinoma, 281
 oncocytoma, 288
- Rh immunization, in bone grafts, 503
- Rhabdoid component, of clear cell renal cell carcinoma, 329-330
- Rolling circle amplification, in pancreatic cancer, 108
- Ron gene mutations, in oncocytoma, 320
- Rosai-Dorfman disease, of breast, cytomorphology of, 705-706
-
- S**
- Sarcoma, renal
 alveolar soft part, 363-367, 369-370
 clear cell, versus metanephric stromal tumor, 387
 synovial, 411-413
- Sarcomatoid carcinoma, renal
 molecular diagnostic techniques for, 291-292
 prognosis for, 419, 440-441
- Scarff-Richardson tumor-grading system, for breast carcinomas, 811-812
- Scars, radial, of breast, cytomorphology of, 695
- Scleral grafts, 620-621
- Sclerosing adenosis, of breast, cytomorphology of, 694
- Sclerosing cholangitis, *CFTR* gene mutations in, 93

- Secretory carcinoma, of breast, cytomorphology of, 767-769
- Semen, banking of, 562-563
- Sentinel lymph nodes, intraoperative imprint cytology in, 795-801
- Serine protease inhibitor. *See* Pancreatic secretory trypsin inhibitor.
- Severe combined immunodeficiency, stem cell transplantation for, 533-534
- Sigmoidoscopy, in colorectal cancer, 151-152
- Silicone breast implants, breast cytomorphology with, 691
- Simpson-Golabi-Behmel syndrome, nephroblastoma in, 343, 346
- Sinus histiocytosis, with massive lymphadenopathy, of breast, cytomorphology of, 705-706
- Sirolimus, for islet cell transplantation, 549-550
- Skin grafts, **587-605**
availability of, 596
banking facilities for, 594-595
clinical uses of, 589-593
cryopreservation of, 600
disadvantages of, 593-594
donor of, 596-597
future of, 601-602
history of, 587-588
indications for, 483
infections from, 593-594
lyophilization of, 600
meshed, 590
minced for micrografts, 592-593
processing of, 598-599
products derived from, 601-602
recovery of, 597-598
refrigeration of, 599-600
rejection of, 594
rewarming of, 601
storage of, 600
substitutes for, 602
testing of, 591-592
transport of, 601
- Smoking, familial pancreatic carcinoma and, 123
- Snaring technique, in colorectal polypectomy, 160
- Soft tissue grafts, **499-518**
alternatives to, 515
complaints about, 514
distribution of, 514
documentation of, 514
freeze drying of, 512-513
incoming, inspection of, 513-514
incorporation of, 501
indications for, 483, 504-505
mechanical properties of, 511-512
packaging of, 509
processing of, 504-505, 508-512
sterilization of, 510-511
storage of, 512-513
types of, 506-508
- Sotos syndrome, nephroblastoma in, 343, 346
- Specimen handling and reporting, for renal cell carcinoma. *See* Renal cell carcinoma(s), specimen handling and reporting for.
- Spherulosis, collagenous, of breast, cytomorphology of, 694
- Spindle cell carcinoma, renal, 393-398
- Spindle cell lesions, of breast, cytomorphology of, 702-703
- SPINK 1. *See* Pancreatic secretory trypsin inhibitor.
- Squamous cell carcinoma, of breast, 761-762
- SSIGN score, for renal cell carcinoma prognosis, 455-456
- Staging
of colorectal cancer, 143-144, 154-158
of nephroblastoma, 346
of renal cell carcinoma, 420, 441-442
- Standards for Tissue Banking*, 595
- Standards of care, malpractice and, 778-779
- Stem cell transplantation, **519-540**
autologous, 519
cell harvesting for, 519
for acute lymphoblastic leukemia, 528-531
for acute myeloid leukemia, 522-524
for aplastic anemia, 524-526
for Hodgkin's disease, 531-532
for islet cell replacement, 552
for lymphoma, 531-532
for neuroblastoma, 526-528
for primary immune deficiencies, 533-534
indications for, 483
selection of cells for, 520-522

- Stereotactic breast biopsy, 664-667
core needle, 636-637
fine needle aspiration, 636-637
- Sterilization
of bone grafts, 510-511
of cardiovascular tissue grafts, 576-577
of soft tissue grafts, 510-511
- STK11* gene mutations, pancreatic carcinoma risk in, 120
- Stomach, cancer of. *See* Gastric cancer.
- Stromal metanephric neoplasms, 384-387
- Sulindac, for colorectal cancer prevention, 159
- Surface-enhanced laser desorption ionization mass spectrometry, in pancreatic cancer, 107
- Synovial sarcoma, of kidney, 411-413
- Systemic inflammatory response syndrome, in pancreatitis, 17
- T**
-
- T lymphocytes, depletion of, for islet cell transplantation, 550-551
- Tacrolimus, for islet cell transplantation, 549-550
- Telomerase
in pancreatic cancer, 104-105
in pancreatic cyst, 109-110
- Telomeric repeat amplification protocol (TRAP), for pancreatic cancer, 105
- Tendon grafts. *See* Soft tissue grafts.
- Testis
cancer treatment toxicity to, 559-560
tissue from, banking of, 560, 562-563
- TFE3* gene fusions, in renal carcinoma, 364-370
- TFE3* gene mutations, in renal cell carcinoma, 292-294
- TFEB-Alpha* gene fusion, in renal carcinoma, 370-375
- TGFβRII* gene mutations, in gastric cancer, 209-210
- Thoenes, Wolfgang Carl, renal tumor classification of, 237, 239
- Thrombospondin 1, in gastric cancer, 211
- Thyroid carcinoma, papillary, papillary renal cell carcinoma with, 272
- Tissue banking
accreditation in, 488-490, 492-493
adverse reaction documentation in, 494
bone, 483, 487, 489, **499-518**
cardiovascular, 483, 488, **571-585**
compensation issues in, 477
credentialing organizations for, 490-493
definition of tissue in, 489-490
disease transmission in
bone grafts, 489
candidiasis, 488
cardiovascular, 575
cytomegalovirus, 593-594
HIV infection, 487, 593, 609
porcine endogenous retrovirus, 552
rabies, 489
regulations on, 488-489
skin grafts, 593-594
distribution sources in, 481
documentation in, 481, 494
donor issues in. *See* Donors, tissue.
eye, 483, **607-624**
facility inspection, 493-495
history of, 473-475
immunology of, 475, 502-503, 579
indications for use of, 483
islet cells, **541-556**
labeling in, 482, 484
overview of, **473-486**
recalls in, 487
regulations for, **487-498**, 609-610
reproductive, **557-569**
skin, 483, **587-605**
soft tissue, 483, **499-518**
state licensing of, 495-496
stem cells, 483, **519-540**
storage in, 481
surgeon responsibilities in, 481-484
- Tissue inhibitor of metalloproteinase 3, in gastric cancer, 211-212
- TNM classification
of colorectal cancer, 144, 156-158
of renal cell carcinoma, 441-442
- Tolerance, induction of, in islet cell transplantation, 550-551
- Tort law, 778
- Training, for breast fine needle aspiration biopsy, 638-640
- Transduction imbalance, in *Helicobacter pylori* infections, 202-203

- Translocation renal neoplasms
 carcinomas, **363-378**
 familial clear cell renal cell carcinoma, 264
 Xp11.2, 292-294, 364-370
 primitive neuroectodermal tumor, 408-410
 synovial sarcoma, 411-413
- Transplantation
 limbal cell, 616-620
 myocardial cells, 580-581
 pancreas, versus islet cell transplantation, 541
 stem cell, 483, **519-540**
 tissue banking for. *See* Tissue banking; *specific tissues*.
- Transrectal ultrasonography, in colorectal cancer, 156-158
- TRAP (telomeric repeat amplification protocol), for pancreatic cancer, 105
- Triple test, in breast lesions, 634, 640-643, 650-651, 733
- Trisomy 7, in papillary renal cell carcinoma, 285
- Trisomy 17, in papillary renal cell carcinoma, 285
- Trisomy 18 (Edwards syndrome), nephroblastoma in, 343, 346
- Tropical calcific pancreatitis, 55, 66-67
- Trypsin
 activation of, 62-63
 early activation of, in pancreatitis, 5-9, 18
 inhibitors of. *See* Pancreatic secretory trypsin inhibitor.
- Trypsinogen
 action of, 62-63
 defects of, in hereditary pancreatitis, 39-46
 early activation of, in pancreatitis, 9-11, 18
- Trypsinogen activation peptide, in pancreatitis, 18, 30-31
- TSC gene mutations, in tuberous sclerosis, 271-272
- Tuberous sclerosis, molecular genetics of, 271-272
- Tubular adenoma, breast, cytomorphology of, 693, 698
- Tubular carcinoma, of breast, cytomorphology of, 736, 741-742
- Tubular pattern, of clear cell renal cell carcinoma, 309
- Tubulocystic carcinoma, 393-395, 398-402
- Tubulocystic pattern, of oncocytoma, 318
- Tumor necrosis factor- α
 in acute pancreatitis, 28-29
 in *Helicobacter pylori* infections, 201
- Tumor suppressor allelic loss analysis
 in pancreatic cancer, 105-107
 in pancreatic cyst, 109
-
- U**
- Ulcerative colitis, colorectal cancer in, 147
- Ultrasonography
 in breast needle biopsy, 663-664, 667-670
 in colorectal cancer, 156-158
- Umbilical cord blood, for stem cell transplantation, 520
- Uniform Anatomical Gift Act, 608
- "The Uniform Approach to Breast Fine Needle Aspiration Biopsy"
 recommendations
 for grading, 747-749
 for report terminology, 753, 756
 versus contemporary practices, **631-654**
 ancillary studies, 646-650
 credentialing, 638-640
 diagnostic terminology, 644-646
 indications, 632-637
 post-FNA, 650-651
 technique, 640-644
 training, 638-640
- Union Internationale Contre le Cancer/
 American Joint Committee on
 Cancer classification, of renal cell carcinoma, 434-440
- University of California-Los Angeles,
 renal cell carcinoma prognostic
 algorithm of, 453-455
-
- V**
- Vacuolating toxin A, of *Helicobacter pylori*, gastric cancer and, 200
- Valves, heart, prosthetic. *See* Cardiovascular tissue grafts.

- Vena cava, inferior, renal cell carcinoma extension into, 445
- VHL* gene mutations
in clear cell renal cell carcinoma, 306
in von Hippel-Lindau disease, 261-263, 281-282
- Videocapsule endoscopy, in colorectal cancer, 164-165
- Vimentin
in clear cell renal cell carcinoma, 253-255
in primitive neuroectodermal tumor, 410
in renal cell carcinoma, 248, 250, 253
- Virchow renal tumor classification, 232
- Virtual colonoscopy, in colorectal cancer, 163-164
- Vitrification, in oocyte preservation, 562
- von Hippel-Lindau disease, molecular genetics of, 259-263, 281-282

W

- WAGR (Wilms' tumor, aniridia, genitourinary malformation, mental retardation), 342-344
- Weichselbaum and Greenish, renal tumor classification of, 233

- Wilms' tumor. *See* Nephroblastoma.
- World Health Organization, renal tumor classification of, 235, 238, 242-244
- Wounds, skin grafts for
full-thickness, 589-590
partial-thickness, 590-591
- WT1* gene mutations
nephroblastoma in, 342-344
nephrogenic rests in, 353
- WT2* gene mutations
nephroblastoma in, 344-345
nephrogenic rests in, 353

X

- Xenotransplantation, of islet cells, 551-552
- Xp11 translocation carcinoma, renal, 292-294, 363-370

Y

- Y chromosome, loss of, in renal papillary adenoma, 286

Z

- Zymogens, activation of, in pancreatitis, 5-9